̽��ֱ��

Researchers have found that the proteins that control the progression of Alzheimer’s are linked in a pathway, and that drugs targeting this pathway may be a way of treating the disease, which affects 40 million people worldwide. ̽��ֱ�� are published today (23 April) in the journal Cell Reports.

̽��ֱ��scientists, from the ̽��ֱ�� of Cambridge, found that as a protein called amyloid precursor protein (APP) is broken down into toxic protein fragments called amyloid-beta, it affects changes in the way that another key protein, tau, behaves. Though links between these proteins have been described in earlier work, this research has identified a new association between them, and found that manipulating the rate at which APP is broken down is directly connected to levels of tau.

While it is not known exactly what causes Alzheimer’s, it is known that amyloid-beta and tau build up in the brain, forming ‘plaques’ and ‘tangles’ which disrupt the connections between neurons, eventually killing them. There are no treatments to stop or reverse the progression of the disease, although researchers are starting to understand the mechanisms which cause it to progress.

Most people who develop Alzheimer’s will first start showing symptoms in later life, typically in their sixties or seventies. However, between one and five percent of individuals with Alzheimer’s have a genetic version of the disease which is passed down through families, with onset typically occurring in their thirties or forties.

̽��ֱ��Cambridge researchers used skin cells from individuals with the genetic form of Alzheimer’s and reprogrammed them to become induced pluripotent stem cells, which can become almost any type of cells in the body. ̽��ֱ��stem cells were then directed to become neurons with all the characteristics of Alzheimer’s.

Working with these clusters of human neurons – in essence, ‘mini brains’ – the researchers used three classes of drugs to manipulate the rate at which APP is ‘chewed up’ by inhibiting the secretase enzymes which are responsible for breaking it into amyloid-beta fragments. By using drugs to increase or decrease the rate at which APP is broken down, they observed that levels of tau can be altered as well.

Earlier research looking into the link between amyloid-beta and tau had found that once the APP gets broken down, a chunk of amyloid-beta gets outside the cell, which triggers increased production of tau. “What we’re seeing is that there’s a second pathway, and that the amyloid-beta doesn’t have to be outside the cell to change levels of tau – in essence, the cell does it to itself,” said Dr Rick Livesey of the Wellcome Trust/Cancer Research UK Gurdon Institute, who led the research.

While the researchers identified this pathway in neurons with the far rarer familial form of Alzheimer’s, they found that the same pathway exists in healthy neurons as well, pointing to the possibility that targeting the same pathway in late-onset Alzheimer’s may be a way of treating the disease.

Dr Simon Ridley, Head of Research at Alzheimer’s Research UK, said: “We are pleased to see that our investment in this innovative research using stem cell technology is boosting our understanding of Alzheimer’s disease mechanisms. Alzheimer’s Research UK is committed to funding pioneering research and through our Stem Cell Research Centre at the ̽��ֱ�� of Cambridge we hope to unpick the molecular changes that cause dementia, and crucially, to test new drugs that halt disease progression. With 850,000 people living with dementia in this country, investment in research to find new treatments is critical.”

̽��ֱ��research also points to the growing importance of human stem cells in medical research. “ ̽��ֱ��question is why hasn’t this pathway been identified, given that Alzheimer’s is so well-studied?” said Livesey. “ ̽��ֱ��answer is that mice don’t develop Alzheimer’s disease, and they don’t respond to these drugs the way human neurons do. It’s something we can only do by looking at real human neurons.”

̽��ֱ��research was funded by Alzheimer’s Research UK and the Wellcome Trust.